Background: Bleeding activates platelets that can bind tumour cells, potentially promoting metastatic growth in patients with cancer. This study investigated whether reoperation for postoperative bleeding is associated with breast cancer recurrence. 
Introduction
Breast cancer is the most common cancer among women, with about 1⋅67 million new patients diagnosed in 2012 1 . With 522 000 annual breast cancer-related deaths estimated worldwide, it is the leading cause of cancer-related death in women in developing countries, and second only to lung cancer in more developed regions 1 .
Surgery, either breast-conserving surgery (BCS) or mastectomy, is the primary treatment for breast cancer. Despite its therapeutic intent, surgery causes physiological stress, which, along with anaesthesia 2 , can lead to transient immunosuppression during the perioperative period 3 . Such transient immunosuppression may lead to poorer immune detection of cancer cells 3 .
Postoperative bleeding requiring reoperation occurs in up to 4 per cent of women undergoing surgery for breast cancer 4 . Depending on the age of the patient and extent of primary surgery (mastectomy versus BCS) 5 , the use of certain prescription drugs (such as selective serotonin reuptake inhibitors (SSRIs) or glucocorticoids) increases the risk of postoperative bleeding requiring reoperation 5, 6 . However, there is no evidence of an effect of SSRIs and glucocorticoid use on breast cancer recurrence 5 -7 . Bleeding activates platelets, which can bind tumour cells, promoting immune evasion, angiogenesis, tumour cell survival and metastatic growth 8 . Cancer is associated with a hypercoagulable state 9, 10 , with heightened platelet activation and a correlation with poor prognosis 11 . Thus, patients with breast cancer who develop postoperative bleeding requiring reoperation may be at increased risk of breast cancer recurrence.
This cohort study was conducted to investigate the association between bleeding occurring within 14 days of primary breast cancer surgery and the rate of recurrence among patients with breast cancer in Denmark.
Methods
This study was approved by the Danish Data Protection Agency (Record 2007-58-0010), the Danish Medicines Agency and the Danish Breast Cancer Group (DBCG). The study is based on routinely collected registry data and according to Danish regulations does therefore not require separate ethical approval.
Setting
This was a nationwide cohort study using Danish population-based registries. Denmark's national health service provides tax-supported healthcare to Danish citizens and permanent residents, including unrestricted access to hospital care and partial reimbursement for prescribed medications 12, 13 . At birth or immigration, each person is assigned a unique civil personal registration number (CPR number) that allows unambiguous individual-level linkage among all Danish administrative and population-based registries, including medical registries 13 .
Source population and data collection
The registry of the DBCG 14, 15 and the Danish National Patient Register (DNPR) was used to identify all women with an incident diagnosis of operable stage I-III breast cancer who underwent BCS or mastectomy between 1996 and 2008. To ensure correct retrieval of the exposure, defined as reoperation for postoperative bleeding within 14 days following primary breast cancer-directed surgery, patients were considered eligible for inclusion in the study if there was a difference of 1 day or less between the recorded date of primary surgery in the DNPR and DBCG database.
The DBCG has registered almost all women with invasive breast cancer in Denmark since 1977 16 . Data on tumour and patient characteristics are collected prospectively by treating physicians. The completeness of registration is approximately 95 per cent 16 . Patients registered in the DBCG database undergo regular follow-up examinations aimed at detecting recurrent disease 17 . The following information was obtained from the DBCG database: age and menopausal status at diagnosis, type of surgery, WHO histological tumour type and grade, lymph node status, tumour size, oestrogen receptor (ER) status, receipt of adjuvant chemotherapy, endocrine therapy (ET) and/or radiation therapy, and date and site of recurrence.
The DNPR has collected data on all non-psychiatric hospital admissions since 1977, and on all outpatient and emergency contacts since 1995. Data in the DNPR include the CPR number, one primary diagnosis, and one or more secondary diagnoses classified according to the ICD, as well as data on diagnostic and surgical procedures 18 .
The DNPR was used to retrieve information on reoperation for bleeding after surgery (Table S1 , supporting information) within 14 days following primary surgery for breast cancer. Information was retrieved from the DNPR on potentially confounding other diseases (co-morbidity) registered up to 10 years before the breast cancer diagnosis. These were summarized using the Charlson Co-morbidity Index (CCI) 19 , modified to exclude breast cancer diagnoses. Co-morbidity prevalent on the date of breast cancer surgery was studied in order to detect diseases that could potentially confound or modify the association between bleeding after surgery and a later breast cancer recurrence 20 -23 . These included: diabetes, liver disease, chronic pulmonary disease, peripheral and cerebral vascular disease, any other cancer, myocardial infarction and congestive heart failure ( Table S2 , supporting information). Information on death and emigration was retrieved from the Civil Registration System (CRS). The CRS, established in 1968, contains information on the vital status of all Danish citizens; it is updated daily 12 .
The National Prescription Registry has automatically recorded detailed information on all prescriptions redeemed at Danish community pharmacies since 1995 24 . Information is transferred electronically into the registry at the time of prescription redemption, so the validity of the registry is extremely high 25 . The registry contains detailed information on dispensed prescriptions, including full Anatomical Therapeutic Chemical codes, and date and quantity dispensed 24 . Data on drugs that potentially confound the association between bleeding and recurrence were retrieved, including simvastatin and aspirin, which may modify breast cancer prognosis 26, 27 , and hormone replacement therapy (HRT) ( Table S3 , supporting information).
Variables analysed
Age at diagnosis was categorized into decades. Histological grade was defined as low, moderate or high, based Values in parentheses are percentages.
on WHO histological tumour type 28 . Stage was classified as I, II or III according to the UICC classification (6th edition) 29 . Lymph node status was defined according to number of involved nodes (0, 1-3, 4 or more). Tumour size was categorized as 20 mm or less, or over 20 mm. ER and adjuvant ET were summarized as: ER+/ET+, ER-/ET-, ER+/ET-or ER−/ET+. Surgery type was either mastectomy or BCS. Treatment with adjuvant chemotherapy was categorized dichotomously. Menopausal status at diagnosis was either premenopausal or postmenopausal, classified according to the DBCG.
Simvastatin and aspirin use were modelled as timevarying co-variables. Longitudinal prescription data were used to define time-updated exposure to these drugs. For each prescription, prescription duration was calculated as pack size (number of pills per pack) multiplied by the number of packages redeemed, assuming that a single pill was taken each day. In defining continuous use, a gap of 30 days was allowed from the end of one prescription (prescription start date + prescription duration) until the start of a new prescription. If a new prescription was redeemed within this window, then exposure was assumed to continue; if not, the patient was considered to have stopped the drug at the end of the 30-day grace period. The patient could later restart if there were further prescriptions. Finally, the resulting time-updated current medical exposure variable lagged by 1 year to allow the effect of the drug to accrue, as any effects on cancer are likely to be delayed, and to minimize confounding by indication. HRT was recorded as a baseline co-variable among women with at least 1 year of prescription history.
Breast cancer recurrence was defined according to the DBCG as any local, regional or distant recurrence, or cancer of the contralateral breast up to 10 years after the primary diagnosis 14 .
Follow-up began 14 days after primary breast cancer surgery (registered in the DNPR) and continued until breast cancer recurrence, death, emigration, 10 years of follow-up or 1 January 2013 (end of the study period), whichever came first. Values in parentheses are percentages. ER, oestrogen receptor; ET, endocrine therapy; RT, radiotherapy; BCS, breast-conserving surgery; HRT, hormone replacement therapy.
Statistical analysis
The proportion of patients with breast cancer who did or did not undergo reoperation for bleeding after surgery was calculated, by patient, tumour and treatment characteristics. Incidence rates (IRs) of recurrence per 1000 person-years were calculated, and the 5-and 10-year cumulative incidence of recurrence was estimated according to whether reoperation for bleeding after primary surgery had been undertaken. IRs were also categorized by time after surgery; recurrences developing within 2 years represented very early recurrence, those diagnosed at 2-5 years comprised early recurrence, and recurrences detected after 5 years represented late recurrence 30 .
The proportion of patients with breast cancer receiving mastectomy and BCS over time was calculated, as was the proportion needing a further operation over time.
Cox regression models with time from start of follow-up as the underlying time scale were used to compute crude and adjusted hazard ratios (HRs) for recurrence The following sensitivity analyses were conducted: changing the 14-day window for reoperation and start of follow-up to 7 days after primary surgery; changing the inclusion criteria from no more than 1 day difference between the recorded date of primary surgery in the DNPR and the DBCG database to no more than 14 days and no more than 31 days; changing the study population to include only patients with stage I and II disease at diagnosis; and excluding patients with previous cancers. 
Reoperation after surgery
Overall, 767 patients (2⋅5 per cent) had at least one reoperation within 14 days of the primary surgery. Compared with women who were not reoperated, a higher proportion of patients who underwent reoperation were postmenopausal (75⋅1 versus 72⋅5 per cent), and had co-morbid disease (CCI score of at least 1: 23⋅2 versus 20⋅1 per cent), a history of cerebrovascular disease (5⋅2 versus 3⋅4 per cent) and moderate-grade tumours (13⋅0 versus 11⋅0 per cent) ( Tables 1 and 2 ). Reoperated patients were more likely to have undergone mastectomy than BCS as primary surgery (69⋅3 versus 57⋅9 per cent) and less likely to receive chemotherapy (28⋅7 versus 33⋅6 per cent). A higher proportion of patients without reoperation had stage III cancer (18⋅1 versus 14⋅0 per cent). Overall, 21⋅0 per cent of women in the breast cancer cohort had been prescribed aspirin or simvastatin during follow-up, and 41⋅6 per cent had been prescribed HRT before the breast cancer diagnosis. Reoperated patients were more likely to be concurrent aspirin users.
Recurrence after reoperation for bleeding
Overall, 4769 patients developed breast cancer recurrence during follow-up. The IR of recurrence was 24⋅0 (95 per cent c.i. 20⋅2 to 28⋅6) and 23⋅1 (22⋅5 to 23⋅8) per 1000 person-years for reoperated and non-reoperated patients respectively ( Table 3) . Regardless of reoperation status, the incidence rate was higher in the first 2 years after surgery, followed by a decrease (Table S4 , supporting information). The 1-year IR of recurrence was 29⋅1 (13⋅1 to 44⋅1) and 21⋅3 (19⋅7 to 23⋅1) per 1000 person-years for reoperated and non-reoperated patients respectively. The IR of recurrence in the second year after primary surgery was 40⋅7 (28⋅3 to 58⋅6) per 1000 person-years for reoperated patients and 34⋅7 (32⋅6 to 36⋅9) per 1000 person-years for non-reoperated patients. After 5 years of follow-up, the IRs for patients who did and did not undergo reoperation were similar: 27⋅7 (22⋅6 to 33⋅9) and 26⋅9 (26⋅1 to 27⋅8) per 1000 person-years respectively. The 5-year cumulative incidence of recurrence was 12⋅8 and 12⋅5 per cent for patients with and without reoperation respectively; the 10-year cumulative incidence of recurrence was 19⋅9 per cent for reoperated patients and 18⋅9 per cent for non-reoperated patients (Table S5 , supporting information). Among 767 patients who underwent reoperation, there were 126 recurrences in 5241 person-years of follow-up. Among 29 944 women who did not undergo reoperation, there were 4643 recurrences in 200 685 person-years of follow-up. After adjusting for potential confounders, no association between bleeding after surgery and breast cancer recurrence was observed (adjusted HR 1⋅06, 95 per cent c.i. 0⋅89 to 1⋅26), regardless of time interval of exposure (7 or 14 days after primary operation) ( Table 3 ). This lack of association did not change in sensitivity analyses in which the study population included only patients with stage I and II disease at diagnosis, patients with previous cancers were excluded, or patients with a difference in surgery date between the DNPR and DBCG database of no more than 14 days and no more than 31 days were included (Table S6 , supporting information). The estimates did not vary by site of breast cancer recurrence (Fig. 1) , and there was no evidence of effect modification in models stratified by age, tumour stage, type of primary surgery or receipt of chemotherapy (Fig. 2) .
Discussion
Previous research in Danish patients reported an association between re-excision (owing to insufficient surgical margins within 2 months of BCS) and increased risk of ipsilateral breast tumour recurrence 31 . This finding was, however, largely explained by residual disease 31 . The hypothesis for the present study was that patients who undergo reoperation for postoperative bleeding would be at increased risk of ipsilateral breast tumour recurrence. No evidence was found of an association between reoperation for bleeding after surgery and later breast cancer recurrence, regardless of time interval of exposure (7 or 14 days after the primary operation). Furthermore, the estimates did not vary in analyses stratified by clinical factors, the extent of primary surgery, or by site of breast cancer recurrence. A slight increase in early recurrence among reoperated patients was observed, but the estimates are imprecise.
Research suggests that mastectomy is associated with a higher risk of intraoperative bleeding and postoperative complications than BCS 32 -34 . However, mastectomy alone and BCS combined with radiotherapy have equal efficacy in terms of preventing breast cancer recurrence 35 .
Results from the present study show that the association of postoperative bleeding with breast cancer recurrence is not modified by the extent of primary surgery.
The associations observed for reoperation and breast cancer recurrence are not in line with those seen in patients undergoing surgery for gastrointestinal cancers. For example, intraoperative blood loss associated with surgery for upper gastrointestinal tract tumours decreases the activity of natural killer cells, which are the body's primary defence mechanism against cancer 36 . Research suggests that blood loss during surgery, regardless of whether blood transfusion is given, is a risk factor for peritoneal recurrence after curative resection of gastric cancer 37 . The mechanisms for the lack of concordance between these findings and those of the present study on breast cancer are unclear. Blood loss that can be controlled by further operation could be less extensive than blood loss that is sufficient to warrant a blood transfusion.
The main strengths of this study include its large size and population-based nationwide design within a setting of universal tax-supported healthcare. The prospective data collection reduced the potential for selection bias and ensured virtually complete follow-up. Furthermore, comprehensive data on potential confounders, including prescription drug data, were available. The crude estimates were quite similar to the adjusted estimates, and thus there was little evidence of confounding. It is also a strength that reoperation for bleeding after surgery has a surgical procedure code and is therefore well recorded in the database. Although the positive predictive value of this specific procedure code has not been assessed in the DNPR, it is expected to be high, as hospitals in Denmark are reimbursed only after registration of surgical procedures. It is nevertheless possible that other operative procedures could be misclassified as reoperation owing to postoperative bleeding. These include the codes for reoperation for postoperative infection or reoperation owing to other causes, which may include insufficient surgical margins (Table S1 , supporting information). However, the latter misclassification is likely to bias the present findings away from the lack of effect of reoperation as residual disease is well known to be associated with recurrence 31 . The impact of postoperative infection on later breast cancer recurrence remains unclear.
Earlier studies 38, 39 used blood transfusion as a proxy for perioperative bleeding. However, in the case of breast cancer surgery, perioperative bleeding does not always result in blood transfusion. Furthermore, patients who receive blood transfusions are often sicker, with disseminated cancer, and more extensive co-morbidity.
The present study has some limitations. Information was missing on the extent of postoperative bleeding, in terms of actual blood loss. There was no information available on surgical complications that may have precipitated such bleeding. Another concern is the risk of selection bias due to exclusion of patients; however, the excluded patients were younger, had less advanced disease stages at diagnosis, and were less likely to receive mastectomy and ET (Table S7 , supporting information). The sensitivity analyses also showed that the inclusion of these patients did not change the present findings ( 40 . During the study interval, all women with metastasis of any size in the axilla were offered axillary clearance level I + II as standard care.
Aspirin has been shown to decrease the risk of breast cancer mortality in some 26 , but not all 41, 42 studies, whereas simvastatin has been consistently associated with a decreased risk of breast cancer recurrence/mortality 43 . Information on prescribed aspirin was available, but it was not possible to account for aspirin bought over the counter. Aspirin formulations are available over the counter in Denmark but, if prescribed, almost exclusively done so in low doses for cardiovascular prevention. Over-the-counter aspirin is available only in small packs, and supplies for regular use are usually prescribed by physicians and reimbursable via the Danish National Health Insurance System. The proportions of total sales of low-dose aspirin dispensed by prescription, and thus captured in prescription registries, is high (92 per cent in 2012) 44 , so residual confounding regarding aspirin is expected to be a minor issue. No information on prescription compliance was available. In Denmark, patients pay part of the cost of redeemed prescriptions, so the estimates are likely to reflect actual use. Adjustment for prescribed aspirin and simvastatin did not change the findings. Finally, despite the large study size, reoperation for postoperative bleeding was relatively rare in this population and thus the precision of some of the estimates is low.
The findings of the present study have important clinical implications, and provide reassurance to patients and physicians that reoperation for postoperative bleeding does not increase the risk of breast cancer recurrence. Patients who undergo reoperation for bleeding are unlikely to need more aggressive adjuvant therapy. Breast cancer surgery involves a soft tissue surface and is often characterized by extensive dissection, which increases the risk of postoperative bleeding; the results may therefore be relevant to other soft tissue surgical procedures. 
